for your Forsite and more 
CGCABLE
834639
KLT
831689
DAYU BIOLOGICAL
871970
4
Fujian Superpipe
300198
5
WuHan Hvsen Biotechnology
300871
US Stock MarketDetailed Quotes
CNM Core & Main
- 50.755
- +1.235+2.49%
Trading Mar 26 11:15 ET
9.65BMarket Cap23.83P/E (TTM)
51.100High49.110Low560.27KVolume49.370Open49.520Pre Close28.20MTurnover0.32%Turnover Ratio23.83P/E (Static)190.06MShares62.15052wk High5.68P/B8.96BFloat Cap37.22052wk Low--Dividend TTM176.54MShs Float62.150Historical High--Div YieldTTM4.02%Amplitude18.750Historical Low50.334Avg Price1Lot Size
Core & Main Stock Forum
Sign in to post a comment
After pulling back during the day, the S&P 500 and Nasdaq hit fresh closing highs- and the Nasdaq hit a trading high of 19,486.15.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ climbed 0.05%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.17%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.40%.
MACRO
JOLTS job openings from the Bureau of Labor Statistics came in at 7.74M, higher than last month's number, but ever since Ap...
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ climbed 0.05%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.17%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.40%.
MACRO
JOLTS job openings from the Bureau of Labor Statistics came in at 7.74M, higher than last month's number, but ever since Ap...
39
10
8
Core & Main's high P/E ratio is due to investors' anticipation of robust future growth. The company's excellent earnings outlook is driving its high P/E. Investors believe the risk of earnings decline isn't significant enough to warrant a lower P/E ratio.
1
Core & Main's acquisition of Dana Kepner is seen as a chance to broaden its geographic reach, diversify its product and service offerings, and incorporate key talent. The merger is expected to provide the water and wastewater industry with unparalleled service.
1
Gapping up
In reaction to earnings/guidance:
• $Coty Inc (COTY.US)$ +3.9%, $General Mills (GIS.US)$+2.6%
Other news:
• $Clene (CLNN.US)$ +5.3% (announces presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension)
• $Clearway Energy-C (CWEN.US)$ +2.5% (Provides operational update on El Segundo Energy Center)
• $Apartment Income (AIRC.US)$ +2.4% (provides operating update)
• $Alpine Immune (ALPN.US)$ +2.3% (...
In reaction to earnings/guidance:
• $Coty Inc (COTY.US)$ +3.9%, $General Mills (GIS.US)$+2.6%
Other news:
• $Clene (CLNN.US)$ +5.3% (announces presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension)
• $Clearway Energy-C (CWEN.US)$ +2.5% (Provides operational update on El Segundo Energy Center)
• $Apartment Income (AIRC.US)$ +2.4% (provides operating update)
• $Alpine Immune (ALPN.US)$ +2.3% (...
9
1
1
Gapping up
In reaction to earnings/guidance:
• $Bowlero (BOWL.US)$ +3.4%
Other news:
• $Intellia Therapeutics (NTLA.US)$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc (GOGO.US)$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics (ADCT.US)$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
In reaction to earnings/guidance:
• $Bowlero (BOWL.US)$ +3.4%
Other news:
• $Intellia Therapeutics (NTLA.US)$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc (GOGO.US)$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics (ADCT.US)$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
13
1
Gapping up
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
10
3
Gainers:
• $National Vision (EYE.US)$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze (BRZE.US)$ +12.2% (In reaction to earnings/guidance)
• $Oracle (ORCL.US)$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf (WULF.US)$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources (CLR.US)$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
• $National Vision (EYE.US)$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze (BRZE.US)$ +12.2% (In reaction to earnings/guidance)
• $Oracle (ORCL.US)$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf (WULF.US)$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources (CLR.US)$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
8
6
5
Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
14
1
No comment yet
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Clement Lemons : okk
章允量 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
103575541 :
RetireWise : Ho ho ho... Santa Claus is coming to town
Adrianlim90 : 1
View more comments...